Putnam Valley, NY. (October 12, 2016) - A multi-center team of researchers are planning a clinical trial using cardiosphere-derived cells (CDCs) (a heterogeneous cluster of proliferating cardiac cells that include mesenchymal stem cells) to regenerate the tissue and improve function of the heart in patients who have suffered heart attacks (myocardial infarction, MI).
The study will use allogeneic CDCs - cells derived from donors other than the patients. In previous pre-clinical and clinical studies, CDCs have been shown to have low immunogenicity and unlikely to result in immune rejection of the cells.
The study, a randomized, double-blind, placebo-controlled phase 1 and 2 study to determine safety, will be carried out by researchers at Cedars-Sinai Heart Institute, Minneapolis Heart Institute, Scripps Medical Center, University of California at San Diego, Duke Clinical Research Institute, Johns Hopkins Hospital, and Columbus Biometrics. The study design and rationale will be published in a future issue of Cell Transplantation and is currently freely available on-line as an unedited, early epub at: http://www.
The team's previous studies have revealed that CDC transplantation was safe and helped improve ventricular function and reduce scar tissue.
"CDC transplantation has been shown to improve the outcome in infarcted myocardium and has an excellent safety profile," said Dr. Timothy D. Henry, Director of the Division of Cardiology, Cedars-Sinai Heart Institute. "While autologous transplantation has been shown to curtail immune responses, obtaining CDCs from the patients is not feasible as it is cost-prohibitive and is associated with many logistical complications. Use of other-donated allogeneic cells, however, allows for more efficient processing and transplantation and previous studies have shown significant improvement and tolerability in subjects without the need for immunosuppression."
Named the "ALLogeneic Heart STem Cells to Achieve Myocardial Regeneration" (ALLSTAR) trial, the study is the first randomized, double-blind, placebo-controlled trial to determine the safety and efficacy of allogeneic CDCs for patients with MI.
The study will examine several clinical endpoints that indicate cardiac regeneration, including cardiac and clinical function, quality of life, symptom alleviation, and safety.
Based on the results of the ALLSTAR Phase 1 trial, researchers predict that infusing CDCs will result in improvement for patients with MI.
"Cultural and lifestyle factors, as well as the increasing age of the population, have culminated to make heart health a significant area of interest in medicine," said Dr. Shinn-Zong (John) Lin, Tzu Chi Hospital, Hualien City, Taiwan, and Co-Editor-in-Chief of Cell Transplantation. "Cell therapy may play an integral role in the way that heart diseases are treated. This clinical study may hold promise for future approaches for treating MI."
Contact: Timothy D. Henry, 127 S. San Vicente Blvd., Suite A3100, Los Angeles, CA 90048
Tel: (424) 315-2699
Fax: (310) 423-3522
Citation: Chakravarty T, Makkar RR, Ascheim D, Traverse JH, Schatz R, DeMaria A, Francis GS, Povsic TJ, Smith R, Lima JA, Pogoda, JM, Marban L, Henry TD. ALLogeneic Heart STem Cells to Achieve Myocardial Regeneration (ALLSTAR) trial: Rationale & Design. Cell Transplant. Appeared or available on-line: August 18, 2016.
The Co-Editors-in-Chief for CELL TRANSPLANTATION are at the Department of Neurosurgery and Brain Repair, Morsani College of Medicine, University of South Florida, Tampa, FL, USA and the Center for Neuropsychiatry, China Medical University Hospital, TaiChung, Taiwan. Contact: Paul R. Sanberg at firstname.lastname@example.org, Shinn-Zong Lin at email@example.com, or Associate Editor Samantha Portis at firstname.lastname@example.org